Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Journal for ImmunoTherapy of Cancer

Figure 2

From: MAGE-specific T cells detected directly ex-vivo correlate with complete remission in metastatic breast cancer patients after sequential immune-endocrine therapy

Figure 2

Patient 1 antigen-specific responses pre and post IMQ treatment. Ex-vivo MAGE and PRAME specific CD8+ (A) and CD4+ (B) T cell responses from bulk PBMCs of Patient 1 pre and post (post treatment and long term follow up 1 and 2) IMQ treatment were evaluated by intracellular cytokine staining for IFN-γ and TNF-α. CD8+ and CD4+ T cells were bead sorted from PBMCs collected post IMQ treatment and in vitro stimulated with CD8 and CD4 depleted PBMCs pulsed with MAGE or PRAME OLPs for 14-20 days. MAGE or PRAME specific CD8+ (C) and CD4+ (D) T cell responses were analyzed by intracellular cytokine staining for IFN-γ and TNF-α. Note that the flow plot for Prame looks different due to issues during acquisition of sample with too few cells. As controls, T cells were also stimulated with MOG and CEF OLPs and PMA/Ionomycin.

Back to article page